Monday, June 16, 2014

Cancer drug may boost cancer-killing virus

Balveen Kaur, PhD, conducted
the study combining bortezomib
and viral therapy
CANCER DIGEST – June 16, 2014 – Adding a low-dose of a targeted drug used to treat a type of bone marrow cancer to a cancer-killing virus therapy might increase the effectiveness of such viral therapy, an early laboratory and animal study shows. Researchers at Ohio State University tested the combination of a herpes virus engineered to kill cancer cells and boretezomib (Velcade®) an FDA-approved drug that targets cell complexes that breakdown proteins in cells. They published their findings in the journal Clinical Cancer Research. The study is a long way from human trials, but is a first step needed to show that a treatment strategy is worth pursuing. In the series of experiments in laboratory cultures of cancer cells, and in animal models of human tumors, the combination treatment suppressed brain tumor growth by 92 percent relative to comparison tumors, with six of eight tumors completely eradicated 23 days after treatment. Similar outcomes were seen in models of head and neck cancers.

No comments:

Post a Comment